Malignant Ependymoma

Malignant ependymoma is a fast-growing cancer that starts from ependymal cells. These cells line the fluid-filled spaces inside the brain and spinal canal. In older naming systems this tumor was called “anaplastic ependymoma” or “WHO grade 3 ependymoma.” Today, experts classify ependymomas mainly by where they arise (supratentorial/upper brain, posterior fossa/back of the brain, or spinal cord) and by their molecular features (specific gene fusions or methylation patterns). Tumors with “grade 3” behavior grow quicker, invade nearby tissue, and are more likely to come back after treatment. PMC+1

Malignant ependymoma is a fast-growing tumor that starts from ependymal cells—the thin lining that covers the fluid-filled spaces inside the brain and the central canal of the spinal cord. Doctors now classify ependymomas by where they grow (supratentorial/above the tentorium, posterior fossa/near the cerebellum, or spinal) and by molecular markers seen on the tumor’s genes. In the 2021 WHO system, many supratentorial tumors are defined by fusions called ZFTA or YAP1; the spinal form can include a very aggressive MYCN-amplified subtype. “Anaplastic/grade 3” was used in older systems; today, grading integrates location, histology, and molecular features to guide care. The main treatments are surgery and focused radiotherapy; chemotherapy has a limited role, mostly for relapse or special pediatric situations. PMC+2Frontiers+2

Because “malignant ependymoma” is a broad, older umbrella term, doctors now try to name the exact subtype (for example, “supratentorial ependymoma, ZFTA-fusion positive” or “posterior fossa ependymoma, PFA”). This precise naming helps predict behavior and plan treatment. PMC+1

---

Other names

• Anaplastic ependymoma (historical name for aggressive/grade 3 disease)

• Grade 3 ependymoma (malignant)

• Supratentorial ependymoma, ZFTA fusion-positive (previously “RELA fusion-positive”)

• Supratentorial ependymoma, YAP1 fusion-positive

• Posterior fossa ependymoma, PFA (often more aggressive in children)

• Posterior fossa ependymoma, PFB

• Spinal ependymoma

These are part of the modern WHO CNS5 system that emphasizes location and molecular biology. PMC+2PMC+2

---

Types

1. Supratentorial (upper brain) ependymoma, ZFTA fusion-positive.
   Driven by fusions involving the ZFTA gene (formerly called RELA). These tumors commonly show L1CAM on immunostaining and tend to behave more aggressively than YAP1-fusion tumors. PMC+2PMC+2

2. Supratentorial ependymoma, YAP1 fusion-positive.
   Less common, often in very young children, and usually has a more favorable course compared with ZFTA-fusion tumors. ScienceDirect

3. Posterior fossa (back of the brain) ependymoma — PFA and PFB.
   PFA and PFB are defined by DNA methylation patterns. PFA often shows loss of the histone mark H3K27me3 (frequently through EZHIP overexpression) and has a higher risk profile; PFB typically occurs in older children/young adults and often behaves better. Frontiers+2BioMed Central+2

4. Spinal ependymoma.
   The most common adult ependymoma; many show NF2 gene alterations or chromosome 22q loss. Behavior varies; complete surgical removal is strongly linked with outcome. PMC

Note: Myxopapillary ependymoma (now WHO grade 2) and subependymoma (grade 1) are related ependymal tumors but are not usually called “malignant.” The term here focuses on the aggressive (grade 3-like) behavior within the modern subgroups. PMC

---

Causes and risk factors

Scientists do not know a single “one cause” for ependymoma. Instead, a mix of genetic drivers and patient factors increases risk or shapes behavior. Below are the best-supported items first, followed by emerging factors under study.

1. ZFTA gene fusions (supratentorial).
   Many upper-brain tumors are driven by rearrangements that fuse ZFTA to other genes. This activates pathways that push cells to divide and survive. It is a defining feature of one subtype. PMC+1

2. YAP1 gene fusions (supratentorial).
   A smaller group has YAP1 fusions. These tumors tend to act less aggressively than ZFTA-fusion tumors, especially in very young children. ScienceDirect

3. Loss of H3K27me3 in PFA.
   Many PFA tumors lose a key histone mark (H3K27me3), often through EZHIP overexpression. This epigenetic change reprograms tumor cells and is a hallmark of high-risk pediatric PFA disease. BioMed Central+1

4. EZHIP overexpression.
   The protein EZHIP blocks PRC2 function and drives global H3K27me3 loss, which supports tumor growth in PFA ependymoma. Nature

5. Chromosome 1q gain.
   Extra copies of arm 1q are repeatedly linked with earlier relapse and worse outcomes, especially in PFA. PMC+2BioMed Central+2

6. Combined 1q gain with 6q loss (PFA).
   When both occur together, risk appears even higher in several series. SpringerLink+1

7. NF2 gene changes (spinal).
   Adult spinal ependymomas often show NF2 mutations or 22q loss; people with neurofibromatosis type 2 (NF2) have a higher tendency to develop spinal ependymomas. PMC+2BioMed Central+2

8. Extent of surgical removal (not a cause, but a strong outcome driver).
   Residual tumor after surgery is one of the most consistent predictors of earlier recurrence. This reflects biology and location. BioMed Central

9. PFB-specific chromosomal changes.
   In PFB, different copy-number patterns (e.g., 13q loss) may influence risk, although 1q gain is less clearly adverse than in PFA. ResearchGate

10. CDKN2A/2B deletion (select cohorts).
    Loss of these cell-cycle brakes has been tied to more aggressive behavior in some series. SpringerLink

11. Epigenetic program by location and age.
    The methylation “fingerprint” that defines PFA vs PFB likely reflects developmental cell-of-origin and helps drive behavior. Frontiers

12. Structural genomic alterations beyond 1q/6q.
    Broad structural changes (copy-number shifts) correlate with poorer survival in posterior fossa ependymoma. BioMed Central

13. Pathologic features of high grade (mitoses, necrosis, microvascular proliferation).
    These features mirror faster growth and are associated with worse outcomes, which is why they historically defined “anaplastic” ependymoma. BioMed Central

14. Tumor microenvironment and hypoxia (emerging).
    Research suggests that stromal signals and low-oxygen niches may help tumor cells survive; this remains an area of study. BioMed Central

15. Angiogenesis signaling (emerging).
    Some ependymomas express factors that promote blood-vessel growth; the clinical impact varies across subtypes. BioMed Central

16. Notch and other developmental pathways (emerging).
    Aberrant activity in pathways that guide neural development has been described in subsets of ependymoma. BioMed Central

17. Rare familial susceptibility.
    Very uncommon families with ependymoma exist (especially spinal), suggesting inherited risk in rare cases. Nature

18. Patient age.
    Younger children are more likely to have PFA tumors; age relates to subtype and risk, not a direct cause. Frontiers

19. Tumor location.
    Location (supratentorial vs posterior fossa vs spinal) determines the dominant molecular drivers and patterns of spread. PMC

20. CSF spread at diagnosis.
    Seeding through cerebrospinal fluid reflects aggressive biology and raises relapse risk; it guides staging and radiotherapy plans. PMC+1

---

Common symptoms

Symptoms depend on where the tumor is and how fast it grows. Many are due to pressure on the brain, blockage of cerebrospinal fluid, or compression of the spinal cord or nerves.

1. Headache that is worse in the morning (raised pressure).

2. Nausea and vomiting without stomach illness, often with headaches.

3. Balance problems or clumsiness, especially with posterior fossa tumors.

4. Neck stiffness or torticollis in young children with posterior fossa tumors.

5. Double vision or abnormal eye movements if cranial nerves are affected.

6. Facial weakness or numbness from brainstem or nerve involvement.

7. Hearing loss or ringing if pathways near the cerebellopontine angle are involved.

8. Seizures for supratentorial tumors.

9. Behavior or school performance change in children (subtle early sign).

10. Back pain for spinal tumors, often steady and worse with strain.

11. Weakness in arms or legs (spinal cord compression).

12. Numbness or tingling (sensory tracts or roots affected).

13. Bowel or bladder trouble with lower spinal involvement.

14. Neck or radicular arm pain with cervical cord tumors.

15. Weight loss or fatigue as a general effect of chronic illness.

These patterns are well described across modern reviews and patient summaries, with seizure-predominance in supratentorial disease and gait/cranial nerve signs more common in posterior fossa tumors. PMC+1

---

Diagnostic tests

A) Physical examination

1. General neurologic exam.
   The doctor checks alertness, memory, speech, and orientation. They look for signs of raised pressure (papilledema) and focal deficits to localize the tumor.

2. Cranial nerve testing.
   Eye movements, face strength, hearing, swallowing, and tongue movement are tested to spot brainstem or posterior fossa involvement.

3. Cerebellar tests.
   Finger-to-nose, heel-knee-shin, and rapid alternating movements reveal clumsiness (ataxia) from posterior fossa tumors.

4. Gait and balance tests.
   Tandem walk and Romberg help detect balance problems.

5. Spinal cord screen.
   Muscle tone, reflexes, sensory level, and sphincter tone are checked to detect cord compression from spinal ependymoma.

These bedside findings guide urgent imaging and correlate with tumor location described above. PMC

B) Manual bedside maneuvers

6. Manual muscle testing.
   The examiner grades strength against resistance in key muscle groups to map weakness to a specific root, cord level, or brain area.

7. Sensory mapping.
   Light touch, pin, vibration, and position sense are checked by hand tools (cotton, pinwheel, tuning fork) to find a sensory level.

8. Provocative neck/back maneuvers.
   Gentle range-of-motion and straight-leg-raise can reproduce radicular pain from root irritation in spinal disease.

9. Vestibular/oculomotor checks.
   Gaze holding, saccades, and head-impulse can uncover brainstem or cerebellar pathway involvement that fits posterior fossa ependymoma.

C) Laboratory & pathological tests

10. Lumbar puncture for CSF cytology (selected cases).
    In suspected spread through the CSF, doctors examine spinal fluid under a microscope to look for tumor cells; timing and protocols (often before surgery) reduce false positives. Cancer.gov

11. Routine blood tests.
    There is no blood tumor marker for ependymoma. Bloodwork is used to assess fitness for surgery and monitor treatment effects (for example, marrow function during chemo), not to diagnose the tumor.

12. Surgical pathology (the gold standard).
    Under the microscope, ependymomas show perivascular pseudorosettes and sometimes true ependymal rosettes. These patterns confirm ependymal origin. Wiley Online Library

13. Immunohistochemistry (IHC).
    Tumor cells typically stain for GFAP and S-100 (glial markers) and often show EMA in a dot-like or ring-like pattern. In ZFTA-fusion cases, L1CAM is a useful surrogate; loss of H3K27me3 supports PFA. PMC+1

14. Molecular testing for fusions and methylation class.
    Testing can detect ZFTA or YAP1 fusions and assign methylation class (PFA/PFB), which now guides diagnosis and prognosis in WHO CNS5. PMC+1

15. Copy-number analysis.
    Detects 1q gain, 6q loss, and other changes that refine risk in posterior fossa tumors. BioMed Central+1

D) Electrodiagnostic tests

16. EEG (for seizures).
    If seizures occur (more common with supratentorial tumors), EEG helps classify events and guide antiseizure treatment while the tumor is being managed. (Supported by standard neuro-oncology practice aligned with symptom patterns above.) Cancer.gov

17. Evoked potentials (selected spinal/brainstem cases).
    Somatosensory or brainstem auditory evoked responses can help assess pathway integrity pre-op and may be used for intraoperative monitoring.

E) Imaging tests

18. MRI brain with contrast (primary test).
    MRI is the best imaging method to locate the mass, define its borders, show enhancement patterns, cysts, calcifications (sometimes better seen on CT), and involvement of surrounding structures. Diffusion, perfusion, and spectroscopy can add clues. PMC

19. MRI spine with contrast.
    Because ependymoma can spread through CSF, imaging of the entire brain and spine is recommended at diagnosis (and again in follow-up as guided by risk). Cancer.gov

20. Craniospinal staging and treatment planning.
    Findings on MRI determine if craniospinal irradiation is needed (for proven CSF/spinal spread) and where to boost radiation dose. PMC+1

Non-pharmacological treatments (therapies & others)

1) Maximal safe surgical resection. The goal is to remove all visible tumor while protecting vital brain or spinal functions. A complete resection improves control and survival; repeat surgery may be considered at recurrence if feasible. PMC

2) Early postoperative MRI & staging. MRI of brain (and often spine) within 24–48 hours checks for residual tumor; staging looks for spread in the spinal axis. This timing improves accuracy and guides the radiation plan. siope.eu+1

3) Precision external-beam radiotherapy (photons). Highly conformal techniques (IMRT/VMAT) focus dose on the tumor bed and margins while limiting exposure to normal brain or cord, reducing late effects. SpringerLink

4) Proton-beam radiotherapy. Protons drop off dose beyond the target (“Bragg peak”), which can reduce risks to hearing, cognition, endocrine function, and growth in children, with strong disease control data. PMC+1

5) Stereotactic radiosurgery (SRS) / hypofractionated boost. For small postoperative remnants or limited recurrences, highly focused radiosurgery can add local control while minimizing scatter dose. SpringerLink

6) Craniospinal irradiation (CSI) when indicated. If imaging shows tumor cells in spinal fluid or drop metastases, CSI treats the whole neuro-axis; otherwise focal fields are preferred to limit toxicity. SpringerLink

7) Structured neuro-rehabilitation (PT/OT/SLP). Physical therapy, occupational therapy, and speech-language therapy help regain strength, balance, coordination, self-care skills, speech, and swallowing; programs improve function and quality of life. Frontiers+1

8) Cognitive rehabilitation & school/work support. Therapist-guided memory, attention, and problem-solving training counters treatment-related cognitive changes and eases return to school or work with accommodations. btrt.org+1

9) Fatigue management (exercise + CBT/mindfulness). The best evidence for cancer-related fatigue combines graded activity with cognitive-behavioral or mindfulness programs; these help during and after treatment. PubMed

10) Nutrition care. Early screening for weight loss and poor intake, counseling, protein-energy support, and (if needed) enteral/parental nutrition follow evidence-based oncology nutrition pathways; high-dose micronutrients are discouraged. PubMed+1

11) Endocrine surveillance (especially in children). Cranial/posterior fossa radiation can affect pituitary and thyroid axes; scheduled checks for growth, puberty, thyroid, adrenal, and gonadal function enable timely hormone replacement. PMC+1

12) Hearing preservation strategies. Proton planning and careful dose constraints lower cochlear dose; early audiology support helps detect and address hearing changes after posterior fossa therapy. PMC

13) Seizure safety education. Most patients without seizures do not need preventive anti-seizure drugs; when seizures occur, counseling on triggers, driving, and safety is essential. PMC

14) Psychosocial support & counseling. Professional counseling and peer support reduce anxiety, depression, and caregiver stress; integrating psychology into care improves coping and adherence. Frontiers

15) Symptom-directed integrative approaches. Evidence-informed integrative care (e.g., mindfulness, yoga, acupressure) can help selected symptoms when coordinated with oncology teams; avoid unproven “cures.” ASCO Publications+1

16) Pain and spasticity non-drug measures. Positioning, stretching, heat/cold, and assistive devices can reduce musculoskeletal pain and tone issues after surgery/radiation. PMC

17) Fall prevention & home safety. Vestibular therapy, balance training, and home modifications reduce injury risk in patients with gait or coordination problems. PMC

18) Vaccination & infection prevention. Usual inactivated vaccines are appropriate unless your oncology team advises otherwise; hygiene and food safety matter during therapy-related immunosuppression. eano.eu

19) Palliative care integration. Palliative teams manage symptoms (pain, fatigue, mood, insomnia) and support decision-making at any stage—this improves quality of life without replacing active treatment. eano.eu

20) Structured follow-up imaging. Regular MRI detects treatable recurrences early; many programs image every 3–4 months for 2–3 years, then less often, individualized by age, site, and risk. Wiley Online Library

---

Drug treatments

Important: In ependymoma, chemotherapy is not standard upfront and shows modest activity; drug choices are individualized in relapse, clinical trials are strongly encouraged, and doses must be set by your oncology team. SpringerLink+1

1) Temozolomide (alkylator). Typical neuro-oncology schedule is 150–200 mg/m² daily for 5 days every 28 days. Purpose: salvage at recurrence. Mechanism: adds methyl groups to tumor DNA, causing damage. Side effects: low blood counts, fatigue, nausea. Small series show limited but sometimes meaningful control in recurrent ependymoma. FDA Access Data+1

2) Cisplatin (platinum). Doses vary by protocol (e.g., 60 mg/m²/day ×2 q3–4 weeks in pediatric brain tumor trials). Purpose: salvage, often in combinations. Mechanism: DNA cross-links. Side effects: kidney injury, neuropathy, hearing loss, nausea. Response rates exist, but survival benefit is unclear. PubMed+1

3) Carboplatin (platinum). Often dosed by AUC (e.g., AUC 4–5 q4 weeks) in adult trials; pediatric dosing uses GFR-based targets. Purpose: salvage; sometimes combined with etoposide or cyclophosphamide. Mechanism: DNA cross-links. Side effects: myelosuppression, allergy risk. Evidence shows activity but limited durability. Oxford Academic+1

4) Etoposide (topoisomerase II inhibitor). Commonly 100 mg/m² days 1–3 with platinum agents. Purpose: combination salvage. Mechanism: prevents DNA repair. Side effects: cytopenias, infection risk. Scholars@Duke

5) Vincristine (vinca alkaloid). Typical adult dose 1.4 mg/m² (max 2 mg) in multi-drug regimens. Purpose: combination therapy. Mechanism: blocks microtubules. Side effects: neuropathy, constipation. siope.eu

6) Cyclophosphamide (alkylator). Doses vary widely (e.g., 1–1.5 g/m²) within platinum/etoposide backbones. Purpose: multi-agent salvage. Mechanism: DNA cross-linking. Side effects: cytopenias, hemorrhagic cystitis (prevented with hydration/mesna). Scholars@Duke

7) Ifosfamide (alkylator). Given in combination regimens for recurrent disease when other options are exhausted. Side effects include encephalopathy and renal tubular damage; requires mesna and monitoring. siope.eu

8) Lomustine/CCNU (nitrosourea). Sometimes used off-label in relapse because of CNS penetration; delayed marrow suppression is common, so careful blood count monitoring is required. SpringerLink

9) Procarbazine (alkylator). Used in older multi-agent protocols with nitrosoureas; restricted diet and drug interactions are necessary due to MAO inhibition. SpringerLink

10) Topotecan (topoisomerase I inhibitor). Has been tried off-label as salvage; main toxicities are neutropenia and fatigue. SpringerLink

11) Irinotecan (topoisomerase I inhibitor). Sometimes combined with bevacizumab in other brain tumors; diarrhea and cytopenias limit use. Evidence in ependymoma is limited. SpringerLink

12) Bevacizumab (anti-VEGF antibody). Not disease-modifying for ependymoma but may palliate edema/radiation necrosis; common neuro-oncology dose is 10 mg/kg IV every 2 weeks. Risks include hypertension, bleeding, poor wound healing. FDA Access Data

13) Carboplatin + Etoposide combinations. Multi-drug regimens can induce responses at relapse but have not shown clear survival gains; hematologic toxicity is common. ACS Journals

14) Platinum + Temozolomide combinations. Explored in small studies; toxicity (e.g., ototoxicity with cisplatin) requires caution. Nature

15) Clinical-trial agents (e.g., targeted/HDAC inhibitors). For PF-A biology (EZHIP-associated epigenetic dysregulation), drugs like panobinostat are under investigation; these remain experimental outside trials. PMC

16–20) Additional cytotoxics (e.g., methotrexate, temozolomide re-challenge, nitrosourea combinations) are occasionally used case-by-case in relapse, guided by prior exposure, blood counts, renal/hepatic function, and goals of care—ideally in a trial setting. SpringerLink

Why so cautious about chemotherapy here? Multiple reviews and guidelines conclude chemo has unproven survival benefit in ependymoma and is mainly a salvage option when surgery/radiation are not possible. siope.eu+1

---

Dietary molecular supplements

Important: Supplements do not treat ependymoma. Oncology nutrition guidance favors meeting needs with food first; use supplements only to correct a deficiency or for a specific symptom, and always clear them with your care team to avoid interactions. PubMed

1) Vitamin D (correct deficiency). Many patients have low 25-OH vitamin D. Checking a level and supplementing to the normal range supports bone health during/after therapy. Typical dosing is individualized (often 800–2000 IU/day; higher short-term if very low) per labs. ScienceDirect+1

2) Protein supplement (whey/plant protein). When appetite is poor, a measured scoop in milk or smoothies helps reach protein targets that protect muscle and immune function during recovery. Dose: enough to meet daily protein goals set by the dietitian. PubMed

3) Omega-3 fatty acids (EPA/DHA). Evidence suggests benefits for inflammation and nutrition in some cancers; not a cure. Typical capsules provide 1–2 g/day combined EPA+DHA if your team agrees. PMC+1

4) Probiotics (selected strains). In some studies, specific Lactobacillus/Bifidobacterium products reduced treatment-related diarrhea; avoid in severe immunosuppression and discuss with your team. Dosing follows the labeled CFU of the product used. PMC+1

5) Multivitamin at RDA level. Standard one-a-day doses help cover gaps; high-dose antioxidant regimens are not recommended during active treatment. PubMed

6) American ginseng (Panax quinquefolius) for fatigue. RCTs suggest 2000 mg/day may lessen cancer-related fatigue; do not use without oncology approval due to drug interactions (anticoagulants, etc.). Oxford Academic+1

7) Ginger (nausea support). Commonly used for chemotherapy-related nausea in broader oncology; dose and interactions should be reviewed if you are on blood thinners. ASCO Publications

8) Fiber (soluble fiber, e.g., psyllium). Helps bowel regularity when opioids or inactivity cause constipation; start low and hydrate. PubMed

9) Calcium with vitamin D (bone health). Helpful if steroid exposure or hypogonadism increases bone loss risk; dosing is individualized to diet and labs. Clinical Nutrition Journal

10) Melatonin (sleep/circadian issues). Mixed evidence; limited brain-tumor studies suggest possible sleep benefits but no survival advantage—use only with clinician guidance (often 2–5 mg at bedtime). PMC+1

---

Immunity/regenerative/stem-cell” therapies

These are investigational, not standard care. Ask about trials at major centers.

1) HER2-targeted CAR-T cells (locoregional). Early-phase pediatric trials are testing intraventricular/intratumoral CAR-T cells against HER2-positive ependymoma; dosing follows strict protocols. Goal: T-cells recognize HER2 on tumor and kill it. Risks include cytokine-release and neurotoxicity. ClinicalTrials.gov+1

2) B7-H3- or HER2-CAR-T platforms (preclinical/early clinical). Laboratory and early reports show antigen recognition in ependymoma models; human dosing is under study. Oxford Academic

3) Dendritic-cell vaccines. Patient-specific immune vaccines are being explored across brain tumors; the aim is to present tumor antigens to the immune system and spark T-cell responses. MDPI

4) Checkpoint inhibitors (e.g., nivolumab). Rare CNS tumor trials include ependymoma cohorts; activity appears limited so far, but research continues. ClinicalTrials.gov

5) Oncolytic viruses (e.g., adenovirus DNX-2401). Designed to infect and lyse tumor cells and stimulate immunity; studied mainly in gliomas, with expanding pediatric CNS protocols. Taylor & Francis Online

6) Epigenetic-targeting strategies (e.g., HDAC inhibitors like panobinostat). PF-A ependymoma biology (EZHIP-linked H3K27me3 loss) motivates trials of drugs that re-set epigenetic marks. PMC

---

Surgeries

1) Posterior fossa craniotomy (brain). Microsurgical removal of tumor near the cerebellum/brainstem to achieve gross total resection and relieve pressure. PMC
2) Supratentorial craniotomy (brain). Resection of tumors above the tentorium with mapping/monitoring to preserve speech, motor, and sensory function. PMC
3) Spinal laminectomy/microsurgical resection. Removal of spinal canal tumor to prevent or reverse weakness, numbness, and bladder/bowel issues. PMC
4) Re-resection at recurrence. Considered when relapse is localized and safely operable; can restore the chance for durable control with re-irradiation. SpringerLink
5) CSF shunt or endoscopic third ventriculostomy. Used if tumor or swelling blocks fluid flow and causes hydrocephalus; the goal is symptom relief and safe delivery of further therapy. SpringerLink

---

Prevention points

There is no known lifestyle way to prevent ependymoma. Focus on secondary prevention (avoiding complications and catching recurrence early). SpringerLink

1. Keep every follow-up MRI and clinic visit. Wiley Online Library

2. Report new headaches, vomiting, or neurological changes quickly. eano.eu

3. Protect hearing during/after therapy with audiology checks when advised. PMC

4. Follow endocrine screening plans for growth, puberty, and thyroid health. PMC

5. Maintain a protein-adequate, energy-adequate diet; seek dietitian help early. PubMed

6. Keep up daily activity as tolerated to fight fatigue and deconditioning. PubMed

7. Practice fall-prevention at home if you have balance or vision issues. PMC

8. Get standard vaccinations unless your oncology team advises otherwise. eano.eu

9. Avoid high-dose unsupervised supplements during active treatment. PubMed

10. Consider clinical-trial screening at relapse for access to newer options. PMC

---

When to see a doctor urgently

Contact your team or go to emergency care for: severe or worsening headache, repeated vomiting, sudden weakness or numbness, new seizures, balance problems or falls, sudden behavior or vision changes, high fever, severe neck/back pain, new bladder/bowel incontinence, or any rapidly worsening symptom after surgery or radiation. These can signal tumor growth, hydrocephalus, bleeding, infection, seizures, or treatment complications that need immediate attention. eano.eu

---

What to eat & what to avoid

What to eat: small frequent meals rich in protein (eggs, fish, legumes, dairy), whole grains for steady energy, fruits/vegetables for fiber and micronutrients, and plenty of fluids. Use oral nutrition shakes if appetite is low. Coordinate any special diets with your oncology dietitian. PubMed
What to avoid: excessive alcohol; unpasteurized or undercooked foods if your counts are low; very high-dose antioxidant/herbal supplements during active treatment; and grapefruit or other interacting foods if your medications list them—always check with your team. PubMed

---

Frequently Asked Questions

1) Is “malignant ependymoma” the same as “anaplastic ependymoma”? “Anaplastic/grade 3” is older wording. Today, site and molecular features (e.g., ZFTA, YAP1, MYCN) better guide risk and therapy. PMC
2) What is the main treatment? Maximal safe surgery followed by focused radiotherapy to the tumor bed. SpringerLink
3) Do children always need proton therapy? Not always, but it’s common because it can spare healthy tissue and reduce late effects while maintaining control. PMC
4) Is chemotherapy standard? No. It’s usually reserved for relapse when surgery/radiation cannot be done again. siope.eu
5) How often will I get MRI scans after treatment? Many centers image every 3–4 months for the first 2–3 years, then space out; your plan will be personalized. Wiley Online Library
6) What are the common long-term issues in children? Possible learning, hearing, and hormone problems—screening helps detect and treat them early. PMC
7) Are seizures common? They can occur, especially with supratentorial tumors; no preventive anti-seizure drugs are needed unless a seizure happens. PMC
8) Can I return to school/work? Yes, with rehab and accommodations; cognitive and physical therapy help. Frontiers
9) Are there promising new treatments? Trials include CAR-T cells (HER2/B7-H3), vaccines, and epigenetic drugs—ask about eligibility if relapse occurs. ClinicalTrials.gov+2Oxford Academic+2
10) Does bevacizumab treat ependymoma? It may reduce swelling or radiation injury but has not shown clear tumor-killing benefit in ependymoma. FDA Access Data
11) What if the tumor spreads to the spine? Your team may recommend craniospinal irradiation plus focused boosts and consider surgery if feasible. SpringerLink
12) Why is early MRI after surgery important? It accurately shows residual tumor before scarring, guiding the radiation plan. siope.eu
13) Can diet or supplements cure ependymoma? No. Nutrition and selected supplements support strength and symptoms but don’t shrink the tumor. PubMed
14) How is fatigue managed best? Exercise plus CBT or mindfulness has the strongest evidence. PubMed
15) Where can I find current guidelines? EANO/EANO-ESMO and NCCN publish management guidance; ask your clinician for the version that matches your age group and tumor site. PMC+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 16, 2025.